Radioactive Iodine Dose Optimization for Graves' Disease by Thyroid Volume

236 patients with Graves' disease received initial single-dose radioactive iodine therapy between August 2022 and August 2024 at a tertiary center in Thailand. The dataset likely contains thyroid volume categories, administered activity per gram, and 6-month outcomes including remission and adverse events. Author Keattichai Keeratitanont published this retrospective study under a CC-BY-4.0 license.

Use Cases

• Modeling remission probability based on thyroid volume and administered radioactive iodine dose.
• Analyzing the relationship between dose escalation and treatment-related adverse events like hypothyroidism.
• Evaluating the efficacy of volume-stratified dosing as an alternative to traditional uptake-based dosimetry.

Strengths

• Dataset includes 236 patient records from a specific tertiary center.
• Outcomes and adverse events were assessed at a standardized 6-month follow-up point.
• Thyroid volume was categorized into four groups and dose into five groups for stratified analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single center in Thailand.

Provenance

Source

figshare

Collection Method

Retrospective study of patients receiving therapy.

Time Range

August 2022 to August 2024

Freshness

Last updated 2026-05-14 04:29:19; freshness should be verified.

Geography

Tertiary center in Thailand